These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23564929)

  • 21. Transient Deformation of Neutrophils in Kawasaki Disease.
    Koike Y; Yanagisawa R; Ogiso Y; Cho Y; Minami K; Takeuchi K; Sakashita K; Higuchi T
    J Pediatr; 2016 Jun; 173():238-241.e1. PubMed ID: 27039225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
    Dale RC; Saleem MA; Daw S; Dillon MJ
    J Pediatr; 2000 Nov; 137(5):723-6. PubMed ID: 11060542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A machine learning approach to predict intravenous immunoglobulin resistance in Kawasaki disease patients: A study based on a Southeast China population.
    Wang T; Liu G; Lin H
    PLoS One; 2020; 15(8):e0237321. PubMed ID: 32853226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Kawasaki disease: corticosteroids revisited.
    Son MB; Newburger JW
    Lancet; 2012 Apr; 379(9826):1571-2. PubMed ID: 22405252
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Kawasaki disease.
    Taddio A; Rosé CD
    N Engl J Med; 2007 Jun; 356(26):2747; author reply 2748. PubMed ID: 17600908
    [No Abstract]   [Full Text] [Related]  

  • 27. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
    Athappan G; Gale S; Ponniah T
    Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis].
    Servel AC; Vincenti M; Darras JP; Lalande M; Rodière M; Filleron A
    Arch Pediatr; 2012 Jul; 19(7):741-4. PubMed ID: 22652521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunoglobulin in suspected Kawasaki disease].
    García Soblechero E; Gómez Santos E; Domínguez Quintero ML; González Vila L
    An Pediatr (Barc); 2010 Sep; 73(3):151-2. PubMed ID: 20605119
    [No Abstract]   [Full Text] [Related]  

  • 32. Significantly Lower Immunoglobulin M Levels 6 Months After Disease Onset in Patients With Kawasaki Disease With Coronary Artery Lesions.
    Chang LS; Chen YJ; Huang PY; Chen KD; Lo MH; Huang YH; Guo MM; Kuo HC
    J Am Heart Assoc; 2021 Jun; 10(12):e020505. PubMed ID: 34096327
    [No Abstract]   [Full Text] [Related]  

  • 33. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC; Touma R; Song Y; Padilla RL; Tremoulet AH; Sidney J; Sette A; Franco A
    Autoimmunity; 2015 May; 48(3):181-8. PubMed ID: 25822882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
    Goto M; Miyagawa N; Kikunaga K; Miura M; Hasegawa Y
    Endocr J; 2015; 62(2):145-51. PubMed ID: 25342092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
    Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Kawasaki syndrome in adults: treatment with polyvalent intravenous immunoglobulins].
    Pavese P; Brion JP; Meusnier T; Stahl JP
    Ann Med Interne (Paris); 1997; 148(3):287-8. PubMed ID: 9255342
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunoglobulin resistance in Kawasaki disease with chronic granulomatous disease.
    Tsuge M; Shigemitsu Y; Yano Y; Fujiwara M; Miyai T; Ueda K; Takata K; Moriwake T
    Pediatr Int; 2012 Jun; 54(3):e32-4. PubMed ID: 22631588
    [No Abstract]   [Full Text] [Related]  

  • 39. Kawasaki disease.
    Kim DS
    Yonsei Med J; 2006 Dec; 47(6):759-72. PubMed ID: 17191303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thinking beyond intravenous immunoglobulin for Kawasaki disease.
    Sage A; Jindal AK; Ramanan AV
    Arch Dis Child; 2023 Oct; 108(10):781-782. PubMed ID: 37567754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.